Rituximab biosimilar - AryoGen Pharmed

Drug Profile

Rituximab biosimilar - AryoGen Pharmed

Alternative Names: Zytux

Latest Information Update: 16 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AryoGen Biopharma
  • Developer AryoGen Pharmed
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD2 antigen inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Microscopic polyangiitis; Non-Hodgkin's lymphoma; Rheumatoid arthritis; Wegener's granulomatosis
  • Phase III Systemic scleroderma

Most Recent Events

  • 22 Jul 2016 Phase-III clinical trials in Systemic scleroderma in Iran (IV) (IRCT2016022126686N1)
  • 26 Feb 2014 Launched prior to this date for Wegener's granulomatosis in Iran (IV)
  • 26 Feb 2014 Launched prior to this date for Chronic lymphocytic leukaemia in Iran (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top